AZ Optimistic On Japan Prospects Despite Pricing, LoE Challenges
While AstraZeneca Japan's sales were flat last year, the UK firm's new country president sees a target of 50 new approvals/indications by 2030 as more than overcoming Forxiga's LoE and a big price cut for Imfinzi.
Scrip - April 15, 2026

Wavelet Aims To Transform Fetal Heart Monitoring With AI, Non-Invasive EEG Tech
Early-stage start-up Wavelet aims to transform fetal heart monitoring, a common obstetric procedure to predict fetal distress and the most common reason for C-sections, with AI-powered fetal EEG monitoring captured non-invasively through the mother’s abdomen.
Medtech Insight - April 14, 2026

CMS Looks To Expand CJR Model Along With Rate Bump In Latest Proposed Rule
Medicare is proposing to expand its Comprehensive Care for Joint Replacement Model, an expired initiative designed to improve care for patients having hip and knee replacements, the most common surgeries among Medicare beneficiaries.
Medtech Insight - April 14, 2026

FDA Budget Request Reflects $1B Planned CDRH Spending
The FDA’s proposed budget narrative reflects a requested 2027 CDRH budget of just over $1bn, up about $86bn from 2026. The increased funds will be spent on user fee activities and enhanced inspections.
Medtech Insight - April 14, 2026

Click Therapeutics Cuts Over 25% Of Staff After $50M Raise, CT-155 Commercial Shift
Click Therapeutics has cut more than a quarter of its workforce as the digital therapeutics developer pivots from research to commercialization. The layoffs follow a $50m Series D investment from Boehringer Ingelheim and a partnership shift.
Medtech Insight - April 14, 2026

EU Beauty Industry Facing First Compliance Deadline For Allergen Labeling
Cosmetic products newly added to the EU market July 31 and afterward must follow the expanded fragrance allergen labeling requirements of Annex III of the EU Cosmetics Regulation.
HBW Insight - April 15, 2026

‘Scale Matters And Portfolio Matters’ – Biocon’s Erick On The US Biosimilars Market
Matt Erick, chief commercial officer for advanced markets at Biocon Biologics, told Generics Bulletin why he foresees consolidation on the way in the US biosimilars sector – but also why no single company can try and tackle the whole market on its own.
Generics Bulletin - April 14, 2026

Ofev Rivals Hit US As Five Firms Get FDA Nod
After a recent loss of exclusivity for Boehringer, five companies are set to launch US generic versions for Ofev, a $3.7bn drug targeted for the treatment of idiopathic pulmonary fibrosis.
Generics Bulletin - April 14, 2026

Organon Clears Legal Overhang In Crowded Denosumab Market
Organon and Henlius have settled US patent litigation with Amgen over denosumab biosimilars, months after launching their products, removing legal uncertainty while highlighting intense competition and pricing pressure in an already crowded market.
Generics Bulletin - April 14, 2026

Henlius Challenges Roche’s Phesgo With First Patient Dosed
Henlius has dosed the first patient in a Phase I trial of HLX319, its subcutaneous pertuzumab/trastuzumab biosimilar to Phesgo. The study marks the first human dosing for the fixed-dose combination in China and underscores Henlius’ push into complex, higher-value oncology biosimilars.
Generics Bulletin - April 14, 2026

In Vivo’s 2026 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the seventh edition of In Vivo's Rising Leaders series.
In Vivo - April 14, 2026

Rising Leaders: Helping EU Device Innovators Clear The Green Agenda’s Hurdles
Attorney at law Jilles van der Hoek co-founded a Green Team within Axon Lawyers to ensure the legal chamber strikes the correct balance between providing support for MDR/IVDR issues and ensuring clients keep their sustainability needs “in sight.”
In Vivo - April 14, 2026

Podcast: How Lilly TuneLab Is Breaking Data Silos In Biotech
Eli Lilly’s Aliza Apple, one of In Vivo's 2026 Rising Leaders, explains how TuneLab uses federated learning and shared ADMET/developability models to give early-stage biotechs plug?and?play, privacy?preserving AI for drug discovery.
In Vivo - April 14, 2026

Rising Leaders 2026: Christina Coughlin’s Pioneering Immuno-Oncology Career
Avacta’s CEO began as a student of cell therapy architect Carl June, and has since held roles at several of the industry’s most innovative oncology companies.
In Vivo - April 14, 2026

In Vivo’s 2026 Rising Leaders
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
In Vivo - April 14, 2026